# Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

> **NCT01943825** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 90 (actual)

## Conditions studied

- Dengue
- Dengue Fever
- Dengue Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** CYD Dengue Vaccine
- **BIOLOGICAL:** CYD Dengue Vaccine
- **BIOLOGICAL:** Japanese Encephalitis Vaccine
- **BIOLOGICAL:** Japanese Encephalitis Vaccine

## Key facts

- **NCT ID:** NCT01943825
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-05
- **Primary completion:** 2015-11-25
- **Final completion:** 2015-11-25
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2022-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01943825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01943825, "Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01943825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*